相关实验视频
Updated: May 15, 2025

04:45
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
Published on: June 2, 2022
2.1K
在ARDS中,CMTM3通过影响肺血管内皮通透性和炎症来调节血管内皮细胞功能障碍
Ziyan Xiao1,2,3, Gang Zhou1,2, Haiyan Xue1,2,3
1Department of Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Frontiers in immunology
|April 8, 2025
概括
化基因类因子超级家族成员CMTM3通过增加血管内皮细胞透性和肺炎,显著影响急性呼吸困扰综合征 (ARDS). 在CMTM3淘汰赛中,小鼠的生存率提高,肺部损伤减少,这突出了CMTM3作为ARDS的潜在治疗点.
科学领域:
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
- 肺部医学 肺部医学
背景情况:
- 急性呼吸困扰综合征 (ARDS) 是一种具有高死亡率的危急疾病.
- 导致ARDS进展的分子机制,特别是涉及血管内皮细胞,需要进一步阐明.
- CMTM3是化学类因子超级家族的成员,在ARDS病变发生过程中起着未知的作用.
研究的目的:
- 研究CMTM3在ARDS的发展和进展中的作用.
- 在ARDS条件下确定CMTM3对血管内皮细胞功能的影响.
- 评估CMTM3作为ARDS的潜在治疗点.
主要方法:
- 在人血管内皮细胞 (HUVEC) 中建立了ARDS模型,使用脂多糖化物 (LPS) 或低氧/低氧化.
- 在刺激的HUVEC中评估CMTM3表达.
- 使用CMTM3过度表达 (adCMTM3) 或淘汰 (shCMTM3) 的HUVEC用于研究细胞透性和炎症标志物 (IL-6,TNF-α) 表达.
- 在一个体内ARDS模型中,CMTM3淘汰赛 (CMTM3ko) 小鼠被生成以评估肺血管透性,肺损伤和生存率.
主要成果:
- 在LPS和缺氧/氧化恢复刺激的HUVEC中,CMTM3表达显著上调.
- 在ARDS条件下,HUVEC中CMTM3的过度表达加剧了细胞透性和IL-6/TNF-α表达.
- 在HUVEC中对CMTM3的抑制减弱了细胞透性和炎症反应.
- 与野生型ARDS小鼠相比,CMTM3淘汰性ARDS小鼠的生存率显著提高,肺损伤和肺血管透率降低.
结论:
- CMTM3通过调节肺血管内皮细胞通透性和肺炎,在ARDS发育中发挥关键作用.
- 准CMTM3是一个有希望的治疗策略,可以减轻ARDS的严重程度并改善患者的治疗结果.
更多相关视频
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K

